HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

BACKGROUND. Vector prime-boost immunization strategies induce strong cellular and humoral immune responses. We examined the priming dose and administration order of heterologous vectors in HIV Vaccine Trials Network 078 (HVTN 078), a randomized, double-blind phase Ib clinical trial to evaluate the s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Bart, Pierre-Alexandre, Huang, Yunda, Karuna, Shelly T., Chappuis, Samuel, Gaillard, Julien, Kochar, Nidhi, Shen, Xiaoying, Allen, Mary A., Ding, Song, Hural, John, Liao, Hua-Xin, Haynes, Barton F., Graham, Barney S., Gilbert, Peter B., McElrath, M. Juliana, Montefiori, David C., Tomaras, Georgia D., Pantaleo, Giuseppe, Frahm, Nicole
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2014
Soggetti:
Clinical Medicine
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4347219/
https://ncbi.nlm.nih.gov/pubmed/25271627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI75894
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi